4.6 Article

Increased Circulating Soluble Junctional Adhesion Molecules in Systemic Sclerosis: Association with Peripheral Microvascular Impairment

Journal

LIFE-BASEL
Volume 12, Issue 11, Pages -

Publisher

MDPI
DOI: 10.3390/life12111790

Keywords

systemic sclerosis; scleroderma; junctional adhesion molecules; sJAM-A; sJAM-C; peripheral microvascular damage; digital ulcers; enzyme-linked immunosorbent assay

Ask authors/readers for more resources

This study investigated the association between serum levels of soluble junctional adhesion molecules (sJAMs) and peripheral vascular clinical features in systemic sclerosis (SSc) patients. The results showed that sJAM-A and sJAM-C levels were significantly increased in SSc patients, especially in those with early/active nailfold videocapillaroscopic patterns and ischemic digital ulcers (DUs). Circulating sJAM-C levels showed good diagnostic accuracy in distinguishing between patients and controls. Logistic regression analysis suggested that sJAM-C might be a better biomarker for SSc-related DUs. These findings provide valuable insights for the prediction and management of DUs in SSc patients.
Systemic sclerosis (SSc, scleroderma) is a severe disease characterized by peripheral microcirculation abnormalities manifesting with Raynaud's phenomenon, nailfold videocapillaroscopic (NVC) changes, and even ischemic digital ulcers (DUs) that are often refractory to treatments. In the wake of previously described associations between the circulating levels of soluble junctional adhesion molecules (sJAMs) and SSc clinical features, here, we measured sJAM-A and sJAM-C levels by enzyme-linked immunosorbent assay in serum samples from a large case series of 110 SSc patients and 85 healthy controls, focusing on their possible association with peripheral vascular clinical features and their potential as biomarkers that are either diagnostic or mirror SSc-related microvasculopathy severity. Our data demonstrated that serum sJAM-A and sJAM-C are significantly increased in patients with SSc vs. healthy controls, especially in those featuring early/active NVC patterns and the presence of ischemic DUs. Moreover, circulating sJAM-C levels showed good diagnostic accuracy in discriminating between patients and controls, as assessed by receiver operator characteristics curve analysis. Finally, logistic regression revealed that, when comparing sJAM-A to sJAM-C, the latter might be better suited as a biomarker for SSc-related DUs. Our promising findings provide the necessary groundwork for longitudinal follow-up analyses of SSc patients aiming to assess whether circulating sJAM-C levels might be predictive for the development of new DUs, as well as DU recurrence and/or refractoriness to targeted therapies.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available